<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Arrowhead Pharmaceuticals, Inc. — News on 6ix</title>
<link>https://6ix.com/company/arrowhead-pharmaceuticals-inc</link>
<description>Latest news and press releases for Arrowhead Pharmaceuticals, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 07 May 2026 20:01:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/arrowhead-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835484878dffbe2df0e3c1e.webp</url>
<title>Arrowhead Pharmaceuticals, Inc.</title>
<link>https://6ix.com/company/arrowhead-pharmaceuticals-inc</link>
</image>
<item>
<title>Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results</title>
<link>https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-reports-fiscal-2026-second-quarter-results</link>
<guid isPermaLink="true">https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-reports-fiscal-2026-second-quarter-results</guid>
<pubDate>Thu, 07 May 2026 20:01:00 GMT</pubDate>
<description>PASADENA, Calif., May 07, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 second quarter ended March 31, 2026. The Company is hosting a conference call today, May 7, 2026, at 4:30 p.m. ET to discuss the results.</description>
</item>
<item>
<title>Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals</title>
<link>https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-licenses-clinical-mash-program-targeting-pnpla3-to-madrigal-pharmaceuticals</link>
<guid isPermaLink="true">https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-licenses-clinical-mash-program-targeting-pnpla3-to-madrigal-pharmaceuticals</guid>
<pubDate>Tue, 05 May 2026 04:00:00 GMT</pubDate>
<description>- Precision approach targets patients who have a mutation in the PNPLA3 gene, which is highly prevalent among Hispanic patients with MASH - Phase 1 data</description>
</item>
<item>
<title>Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events</title>
<link>https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-to-participate-in-upcoming-may-2026-events</link>
<guid isPermaLink="true">https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-to-participate-in-upcoming-may-2026-events</guid>
<pubDate>Mon, 04 May 2026 11:30:00 GMT</pubDate>
<description>PASADENA, Calif., May 04, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the events in which it is scheduled to participate throughout the month of May, 2026.</description>
</item>
<item>
<title>Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS)</title>
<link>https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-receives-tga-approval-of-redemplor-plozasiran-in-australia-expanding-global-access-for-patients-with-familial-chylomicronemia-syndrome-fcs</link>
<guid isPermaLink="true">https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-receives-tga-approval-of-redemplor-plozasiran-in-australia-expanding-global-access-for-patients-with-familial-chylomicronemia-syndrome-fcs</guid>
<pubDate>Fri, 01 May 2026 11:30:00 GMT</pubDate>
<description>PASADENA, Calif., May 01, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the Australian Therapeutic Goods Administration (TGA) has approved REDEMPLO® (plozasiran), a small interfering RNA (siRNA) medicine, as an adjunct to diet to reduce triglyceride levels for adult patients with familial chylomicronemia syndrome (FCS) for whom standard triglyceride lowering therapies have been inadequate. FCS is a severe, rare disease characterized by triglyceride levels that can be</description>
</item>
<item>
<title>Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe</title>
<link>https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-receives-positive-chmp-opinion-recommending-approval-of-redemplor-plozasiran-to-reduce-triglycerides-in-adults-with-familial-chylomicronemia-syndrome-fcs-in-europe</link>
<guid isPermaLink="true">https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-receives-positive-chmp-opinion-recommending-approval-of-redemplor-plozasiran-to-reduce-triglycerides-in-adults-with-familial-chylomicronemia-syndrome-fcs-in-europe</guid>
<pubDate>Fri, 24 Apr 2026 10:39:00 GMT</pubDate>
<description>PASADENA, Calif., April 24, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (EMA CHMP) has adopted a positive opinion, recommending the approval of REDEMPLO® (plozasiran), a small interfering RNA (siRNA) medicine, as an adjunct to diet to reduce triglyceride levels in adult patients with familial chylomicronemia syndrome (FCS). FCS remains widely underdiagnosed and affects an estimated 1 to 1</description>
</item>
<item>
<title>Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Second Quarter Results</title>
<link>https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-to-webcast-fiscal-2026-second-quarter-results</link>
<guid isPermaLink="true">https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-to-webcast-fiscal-2026-second-quarter-results</guid>
<pubDate>Mon, 20 Apr 2026 20:01:00 GMT</pubDate>
<description>PASADENA, Calif., April 20, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 7, 2026, at 4:30 p.m. ET to discuss its financial results for the fiscal 2026 second quarter ended March 31, 2026.</description>
</item>
<item>
<title>Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Session and Expo</title>
<link>https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-presents-new-long-term-efficacy-and-safety-data-for-plozasiran-across-a-spectrum-of-hypertriglyceridemia-at-the-american-college-of-cardiologys-75th-annual-scientific-session-and-expo</link>
<guid isPermaLink="true">https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-presents-new-long-term-efficacy-and-safety-data-for-plozasiran-across-a-spectrum-of-hypertriglyceridemia-at-the-american-college-of-cardiologys-75th-annual-scientific-session-and-expo</guid>
<pubDate>Sat, 28 Mar 2026 04:00:00 GMT</pubDate>
<description>– Patients with severe hypertriglyceridemia (sHTG) achieved an 83% median reduction in triglycerides (TG), with 96% of patients achieving TG levels below 500</description>
</item>
<item>
<title>Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events</title>
<link>https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-to-participate-in-upcoming-march-2026-events</link>
<guid isPermaLink="true">https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-to-participate-in-upcoming-march-2026-events</guid>
<pubDate>Tue, 24 Feb 2026 12:30:00 GMT</pubDate>
<description>PASADENA, Calif., February 24, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:</description>
</item>
<item>
<title>Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results</title>
<link>https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-reports-fiscal-2026-210500386</link>
<guid isPermaLink="true">https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-reports-fiscal-2026-210500386</guid>
<pubDate>Thu, 05 Feb 2026 21:05:00 GMT</pubDate>
<description>PASADENA, Calif., February 05, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 first quarter ended December 31, 2025. The Company is hosting a conference call today, February 5, 2026, at 4:30 p.m. ET to discuss the results.</description>
</item>
<item>
<title>Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600</title>
<link>https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/ciena-set-to-join-sandp-500-arrowhead-pharmaceuticals-to-join-sandp-midcap-400-adt-and-onespaworld-holdings-to-join-sandp-smallcap-600-2</link>
<guid isPermaLink="true">https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/ciena-set-to-join-sandp-500-arrowhead-pharmaceuticals-to-join-sandp-midcap-400-adt-and-onespaworld-holdings-to-join-sandp-smallcap-600-2</guid>
<pubDate>Wed, 04 Feb 2026 23:15:00 GMT</pubDate>
<description>S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600:</description>
</item>
<item>
<title>Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia</title>
<link>https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-initiates-phase-1-123000874</link>
<guid isPermaLink="true">https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-initiates-phase-1-123000874</guid>
<pubDate>Tue, 27 Jan 2026 12:30:00 GMT</pubDate>
<description>PASADENA, Calif., January 27, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-DIMER-PA, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for atherosclerotic cardiovascular disease (ASCVD) due to mixed hyperlipidemia. ARO-DIMER-PA is designed to silence expression of both proprotein convertase subtilisin kexin 9 (PCSK9) and apolipoprotein C3 (AP</description>
</item>
<item>
<title>Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results</title>
<link>https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-webcast-fiscal-2026-213000415</link>
<guid isPermaLink="true">https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-webcast-fiscal-2026-213000415</guid>
<pubDate>Tue, 20 Jan 2026 21:30:00 GMT</pubDate>
<description>PASADENA, Calif., January 20, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 5, 2026, at 4:30 p.m. ET to discuss its financial results for the fiscal 2026 first quarter ended December 31, 2026.</description>
</item>
<item>
<title>Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants</title>
<link>https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-prices-upsized-offerings-040500924</link>
<guid isPermaLink="true">https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-prices-upsized-offerings-040500924</guid>
<pubDate>Thu, 08 Jan 2026 04:05:00 GMT</pubDate>
<description>PASADENA, Calif., January 08, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the pricing of its concurrent public offerings of (i) $625,000,000 aggregate principal amount of 0.00% convertible senior notes due 2032 (the "notes") and (ii) 3,100,776 shares of common stock, at a public offering price of $64.50 per share (or, in lieu of shares of common stock to certain investors, pre-funded warrants, at a public offering price of $64.499 per pre-funded warrant, for up to 1,550,</description>
</item>
<item>
<title>Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China</title>
<link>https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-announces-nmpa-approval-123000759</link>
<guid isPermaLink="true">https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-announces-nmpa-approval-123000759</guid>
<pubDate>Wed, 07 Jan 2026 12:30:00 GMT</pubDate>
<description>PASADENA, Calif., January 07, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the Chinese National Medical Products Administration (NMPA) has approved REDEMPLO® (plozasiran) for the reduction of triglyceride levels in adult patients with familial chylomicronemia syndrome (FCS). FCS is a severe, rare disease characterized by triglyceride levels that can be 10 to 100 times higher than normal leading to a substantially higher risk of developing acute, recurrent, and potent</description>
</item>
<item>
<title>Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock</title>
<link>https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-announces-proposed-offerings-231400976</link>
<guid isPermaLink="true">https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-announces-proposed-offerings-231400976</guid>
<pubDate>Tue, 06 Jan 2026 23:14:00 GMT</pubDate>
<description>PASADENA, Calif., January 06, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its intention to offer, subject to market and other conditions, $500 million aggregate principal amount of convertible senior notes due 2032 (the "notes") and $200 million of common stock in separate public offerings registered under the Securities Act of 1933, as amended. Arrowhead also expects to grant the underwriters of the note offering a 30-day option to purchase up to an additional $75 milli</description>
</item>
<item>
<title>Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition</title>
<link>https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-announces-interim-clinical-123000690</link>
<guid isPermaLink="true">https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-announces-interim-clinical-123000690</guid>
<pubDate>Tue, 06 Jan 2026 12:30:00 GMT</pubDate>
<description>PASADENA, Calif., January 06, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from two Phase 1/2a clinical trials of ARO...</description>
</item>
<item>
<title>Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)</title>
<link>https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-announces-health-canada-approval-redemplotm-plozasiran</link>
<guid isPermaLink="true">https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-announces-health-canada-approval-redemplotm-plozasiran</guid>
<pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
<description>– REDEMPLO is the first and only Health Canada-approved siRNA medicine to be studied in patients with genetically confirmed and clinically diagnosed FCS –</description>
</item>
<item>
<title>Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events</title>
<link>https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-participate-upcoming-january-2026-events-2025-12-23</link>
<guid isPermaLink="true">https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-participate-upcoming-january-2026-events-2025-12-23</guid>
<pubDate>Tue, 23 Dec 2025 05:00:00 GMT</pubDate>
<description>PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following</description>
</item>
<item>
<title>Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-0</link>
<guid isPermaLink="true">https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-0</guid>
<pubDate>Mon, 15 Dec 2025 05:00:00 GMT</pubDate>
<description>PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the</description>
</item>
<item>
<title>Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies</title>
<link>https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-initiates-phase-1-2a-study-aro-mapt-treatment-alzheimers</link>
<guid isPermaLink="true">https://6ix.com/company/arrowhead-pharmaceuticals-inc/news/arrowhead-pharmaceuticals-initiates-phase-1-2a-study-aro-mapt-treatment-alzheimers</guid>
<pubDate>Mon, 08 Dec 2025 05:00:00 GMT</pubDate>
<description>- ARO-MAPT utilizes the Targeted RNAi Molecule (TRiM™) platform designed for subcutaneous administration and systemic delivery to the CNS by crossing the</description>
</item>
</channel>
</rss>